|
Affiliation |
Faculty of Medicine College Hospital Urology |
|
Title |
Assistant Professor |
|
Related SDGs |
|
ABE Junya
|
|
|
Papers 【 display / non-display 】
-
Local treatment for metastatic and primary sites in metastatic renal cell carcinoma in the combination immunotherapy era: a narrative review Invited Reviewed
Abe J., Murashima T., Kojima S., Ueno T., Takei A., Nakai N., Akioka T., Kamoto T., Sawada A.
International Journal of Clinical Oncology 2026
Authorship：Lead author Publishing type：Research paper (scientific journal) Publisher：International Journal of Clinical Oncology
Advances in immuno-oncology (IO)-based systemic therapies have improved treatment outcomes for patients with metastatic renal cell carcinoma (mRCC). However, long-term survival of these patients remains challenging, highlighting the need to reassess the role of local and metastasis-directed treatments. Cytoreductive nephrectomy (CN) has traditionally been a part of the therapeutic armamentarium for mRCC, and evidence from the targeted therapy era—most notably the CARMENA and SURTIME trials—indicates that deferred CN after initial systemic therapy may benefit carefully selected patients. In the IO era, prospective evidence regarding CN is lacking, although ongoing trials, such as NORDIC-SUN and PROBE, are expected to refine patient selection and optimal timing. Real-world analysis reveals a significant decline in conducting CN since 2018. However, CN remains associated with improved overall survival of patients who received several IO-based first-line regimens after adjustment for baseline characteristics. Metastasis-directed treatments, including metastasectomy and local interventions for bone metastases, continue to exhibit potential survival benefits and may maintain functional status when complete resection of lesions is achievable. Considering the absence of definitive prospective data applicable to routine clinical practice, individualized treatment strategies should consider CN and local therapies alongside systemic treatment response, tumor biology, and patient-specific prognostic factors.
-
Abe J., Muranaka T., Kunishima Y.
Urology Case Reports 62 2025.9
Publishing type：Research paper (scientific journal) Publisher：Urology Case Reports
We report the case of an 85-year-old man diagnosed with metastatic prostate cancer three years earlier. While on combined androgen blockade, he developed hematuria, hematochezia, and fatigue. These symptoms were attributed to local progression of prostate cancer and syndrome of inappropriate antidiuretic hormone secretion (SIADH). Water restriction, palliative radiation, and tolvaptan alleviated the symptoms. Four months later, he experienced appetite loss and fatigue due to hypercalcemia, ultimately leading to a diagnosis of humoral hypercalcemia of malignancy (HHM).
-
Abe J., Kyoda Y., Haga K., Sasao T., Nishiyama D., Nofuji S., Ichihara K., Matsuda Y., Toyota T., Ueki Y., Konta S., Nakayama S., Shibuya J., Kobayashi G., Maehana T., Nakajima Y., Masumori N.
International Journal of Urology 32 ( 7 ) 804 - 810 2025.7
Publishing type：Research paper (scientific journal) Publisher：International Journal of Urology
Objective: The Japanese guidelines for male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) recommend the water vapor energy therapy (WAVE) procedure only for patients in whom conventional BPH surgery is unsuitable due to advanced age or comorbidities. This study aims to evaluate the efficacy and safety of the WAVE procedure using the Rezum system in Japan. Methods: This multicenter retrospective study included patients who underwent the WAVE procedure between August 2022 and December 2023. A total of 311 patients from 13 institutions were registered. The number of medications for LUTS was determined before surgery and 6 months after surgery. Additionally, voiding function and perioperative complications were analyzed. Results: Of the 311 patients, 291 were eligible for analysis. The mean number of LUTS medications significantly decreased from 1.4 to 0.6 (p < 0.001). The mean maximum urinary flow rate significantly improved from 9.8 mL/s preoperatively to 12.2 mL/s at 6 months postoperatively (p < 0.001). The mean post-void residual volume also significantly decreased from 124 to 78 mL (p < 0.001). Furthermore, the mean total International Prostate Symptom Score significantly improved from 17.8 to 8.9 (p < 0.001). Complications classified as Clavien–Dindo Grade III or higher occurred in four cases (1.2%). Conclusion: This large-scale, multicenter study demonstrates that the WAVE procedure improves LUTS, reduces the number of LUTS medications, and is both effective and safe for elderly patients with multiple comorbidities in Japan.
DOI： 10.1111/iju.70052
-
Penile Fracture in Japan Resulting from a Habit of Over 30 Years Resembling “Taqaandan” Reviewed
ABE Junya, YAMASHITA Yutaka, YOSHIDA Takashi, KOBAYASHI Ko
71 ( 2 ) 53 - 57 2025.2
Language：Japanese Publishing type：Research paper (scientific journal)
A 52-year-old man presented to our hospital with penile swelling and pain. The patient was injured when he forcibly bent his erect penis and heard a dull sound different from the“usual click sound”in the morning. His penis was bent dorsally with a hematoma and was purplish red. We diagnosed this as penile fracture and performed surgical treatment. We made a circumferential incision and degloved his penile prepuce. We removed the hematoma and repaired the injured tunica albuginea with absorbable sutures. Urethral injury was not found. He had no complications or erectile dysfunction after surgery. He had the habit of hearing the clicking sound caused by bending his erect penis since he was fifteen years old. This habit seems to resemble the“taqaandan”procedure, which was reported in Kermanshah, Iran. Only 14 penile fractures related to the habit resembling taqaandan have been reported in Japan.